Research To Practice | Oncology Videos ER-Positive Breast Cancer | What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of ER-Positive Breast Cancer
Jan 4, 2023
02:04:40
Featuring perspectives from Drs Aditya Bardia, Matthew Goetz, Virginia Kaklamani, Kevin Kalinsky and Hope Rugo, including the following topics:
- Current Role of Genomic Assays for Hormone Receptor (HR)-Positive Localized Breast Cancer
- Introduction (0:00)
- Case: A premenopausal woman in her early 40s with 9-mm, Grade III, ER/PR-positive, HER2-negative, node-negative infiltrating ductal carcinoma (IDC) – 21-gene Recurrence Score® 22 — Alan B Astrow, MD (3:39)
- Case: A premenopausal woman in her mid 30s with 3.6-cm, ER/PR-positive, HER2-low (IHC 1+), sentinel node-positive (4/4) multifocal IDC after bilateral mastectomies, adjuvant AC-T and ovarian function suppression (OFS)/aromatase inhibitor, Ki67 50% — Laila Agrawal, MD (9:40)
- Dr Goetz presentation (19:43)
- Optimizing the Management of Localized ER-Positive Breast Cancer
- Case: A woman in her early 40s with 5.5-cm, ER/PR-positive, HER2-negative, node-positive (20/21) IDC after bilateral mastectomies, bilateral salpingo-oophorectomy, adjuvant AC-T and initiation of letrozole/abemaciclib, Ki-67 3% — Susmitha Apuri, MD (32:22)
- Case: A woman in her mid 50s with de novo ER-positive, PR-negative, HER2-negative ulcerated breast cancer with pulmonary and extensive spinal metastases — Jennifer L Dallas, MD (40:45)
- Dr Kaklamani presentation (45:32)
- Selection and Sequencing of Therapy for Patients with ER-Positive Metastatic Breast Cancer (mBC)
- Case: A woman in her early 50s with ER/PR-positive, HER2-low mBC with a PI3KCA mutation who experiences a dramatic response to rechallenge with fulvestrant and a CDK4/6i (abemaciclib); now with progression and cytopenias — Kapisthalam (KS) Kumar, MD (59:07)
- Dr Kalinsky presentation (1:09:53)
- Recent Appreciation of HER2 Low as a Unique Subset of HR-Positive Breast Cancer
- Case: A premenopausal woman in her late 30s with ER/PR-positive, HER2-low (IHC 1+) IDC after adjuvant tamoxifen and OFS x 5 years, now with bone and liver metastases — Dr Agrawal (1:19:45)
- Dr Bardia presentation (1:24:29)
- Novel Strategies Under Investigation for Patients with HR-Positive mBC
- Case: A woman in her early 90s with ER/PR-positive, HER2-low (IHC 1+) mBC and progressive disease on multiple lines of endocrine and chemotherapy receives T-DXd — Dr Astrow (1:38:44)
- Case: A woman in her mid 40s with ER/PR-positive, HER2-low (IHC 2+) mBC who has received fulvestrant/abemaciclib, now receiving exemestane/everolimus – ESR1 and PIK3CA mutations — Dr Dallas (1:44:15)
- Dr Rugo presentation (1:49:58)